An open study was carried out on the oral effect of perhexiline maleate on angina pectoris. After 2 weeks observation period, during which a placebo was given, a daily dose of 300 mg, divided in 3 times after each meal, administered for 4 weeks in 79 cases of angina pectoris. Beneficial effect was obtained in 77.9% of the cases at the end of 2 weeks administration and in 80.0% at the end of 4 weeks administration, compared with preceding observation period. Two weeks after discontinuation of the drug, the effectiveness reduced to 51.6%, significantly lower than the active treatment period (p<0.001). Number of attacks and the consumption of nitroglycerin tablets showed also significant reduction as compared with the observation period. No remarkable changes were observed in arterial blood pressure, heart rate and cardiothoracic ratio. Side effects occurred in 17 cases. Most frequent one was gastrointestinal disturbance. The drug was required to discontinue in only 2 cases: hemorrhagic stomatitis and skin rash. In conclusion, perhexiline maleate was evaluated as a promising antianginal agent.